NEW YORK (GenomeWeb) – PGXL Technologies today said that it has formed a partnership with NX PharmaGen under which the partners have created a research center focused on exosome analysis.
The PGXL NeXosome Center of Excellence will utilize NX PharmaGen’s NeXosome microparticle enrichment technology to support identification of biomarkers. The partners said they will provide access to the platform and assay development services in a CLIA setting to researchers and biopharmaceutical firms.
The firms said that the NeXosome platform complements PGXL’s existing single-cell separation capabilities, which uses Silicon Biosystems’ DEPArray technology to isolate individual cells for analysis. They said the combined technologies provide “a unique ability to detect cancer long before it appears on even the most discerning scans and imaging technology.” PGXL added that it makes the DEPArray and NeXosome platforms available to individuals and companies researching diagnostic techniques.
Further terms of the agreement were not disclosed.
“As a CLIA-certified lab, PGXL is well-positioned to rapidly commercialize the NeXosome platform, making it available to researchers who wish to pursue their biomarker research with rigor, speed, precision and efficiency,” Roland Valdes, president of Louisville, Ky.-based PGXL, said in a statement.